Zeleris

florfenicol / meloxicam

Table of contents

Opinion

On 15 February 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion1, recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Zeleris. The marketing authorisation holder for this veterinary medicinal product is CEVA Santé Animale. Zeleris is currently authorised as solution for injection for use in cattle. The grouped variation concerns the addition of a new therapeutic indication for the treatment of bovine respiratory disease due to Mycoplasma bovis associated with pyrexia and the alignment of the product information with version 9.0 of the QRD templates. Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.


1 Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Key facts

Name
Zeleris
Agency product number
EMEA/V/C/004099
International non-proprietary name (INN) or common name
  • florfenicol
  • meloxicam
Species
Cattle
Active substance
  • florfenicol
  • meloxicam
Date opinion adopted
15/02/2023
Company name
CEVA Santé Animale
Status
Positive
Application type
Post-authorisation

Related content

How useful was this page?

Add your rating